Compare SPRO & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | SUNS |
|---|---|---|
| Founded | 2013 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 134.6M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | SUNS |
|---|---|---|
| Price | $2.28 | $9.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 281.7K | 108.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | ★ 12.45% |
| EPS Growth | N/A | ★ 1112.46 |
| EPS | N/A | ★ 1.09 |
| Revenue | ★ $40,549,000.00 | $19,384,703.00 |
| Revenue This Year | N/A | $174.58 |
| Revenue Next Year | N/A | $60.45 |
| P/E Ratio | ★ N/A | $8.83 |
| Revenue Growth | N/A | ★ 2540.16 |
| 52 Week Low | $0.51 | $7.80 |
| 52 Week High | $3.22 | $14.72 |
| Indicator | SPRO | SUNS |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 46.17 |
| Support Level | $2.26 | $9.31 |
| Resistance Level | $2.37 | $10.13 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 12.12 | 41.06 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.